Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

VTYX

Ventyx Biosciences Inc

Oct 31 • 04:00PM ET

8.53

+0.11 1.31 %

Healthcare • Biotechnology • USA • NASD

Peers: REGN MRNA VRTX BIIB INCY GILD AMGN NBIX BMRN EXEL

| Held by: VTI SCHA VXF IWC AVSC VHT DFAS SCHB PRFZ QQQS

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.68	Insider Own	10.79%	Shs Outstand	71.23M	Perf Week	46.82%
Market Cap	608.26M	Forward P/E	-	EPS next Y	-1.90	Insider Trans	0.00%	Shs Float	63.62M	Perf Month	141.64%
Enterprise Value	409.59M	PEG	-	EPS next Q	-0.45	Inst Own	63.15%	Short Float	2.20%	Perf Quarter	213.60%
Income	-119.03M	P/S	-	EPS this Y	15.55%	Inst Trans	-8.61%	Short Ratio	0.39	Perf Half Y	488.28%
Sales	0.00M	P/B	2.90	EPS next Y	-13.90%	ROA	-44.15%	Short Interest	1.40M	Perf YTD	289.50%
Book/sh	2.94	P/C	2.91	EPS next 5Y	1.75%	ROE	-48.56%	52W High	8.52 0.12%	Perf Year	256.90%
Cash/sh	2.93	P/FCF	-	EPS past 3/5Y	-5.26% -87.13%	ROIC	-54.46%	52W Low	0.78 989.40%	Perf 3Y	-70.36%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	15.36% 11.89%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	39.76%	Oper. Margin	-	ATR (14)	0.76	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	19.12	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	83.12	Recom	1.44
Dividend Gr. 3/5Y	- -	Current Ratio	19.12	EPS Q/Q	16.30%	SMA20	70.46%	Beta	1.24	Target Price	12.14
Payout	-	Debt/Eq	0.05	Sales Q/Q	-	SMA50	137.32%	Rel Volume	1.53	Prev Close	8.42
Employees	82	LT Debt/Eq	0.04	Earnings	Aug 07 AMC	SMA200	267.86%	Avg Volume	3.61M	Price	8.53
IPO	Oct 21, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	19.15% -	Trades		Volume	5,419,095	Change	1.31%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-12-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$7 → $16
Mar-12-24	Upgrade	Oppenheimer	Perform → Outperform	$12
Nov-07-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$77 → $8
Nov-07-23	Downgrade	Stifel	Buy → Hold	$6
Nov-07-23	Downgrade	Oppenheimer	Outperform → Perform
Nov-07-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$46 → $6
Nov-07-23	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-14-23	Resumed	Credit Suisse	Outperform	$63
Mar-21-23	Initiated	Wells Fargo	Overweight	$77
Dec-19-22	Initiated	Goldman	Buy	$50
Nov-17-22	Initiated	Morgan Stanley	Overweight	$45
Sep-07-22	Initiated	Stifel	Buy	$45
Sep-01-22	Initiated	H.C. Wainwright	Buy	$36
May-09-22	Initiated	Credit Suisse	Outperform	$53
Mar-31-22	Initiated	Canaccord Genuity	Buy	$30
Feb-01-22	Initiated	Oppenheimer	Outperform	$30
Nov-15-21	Initiated	Piper Sandler	Overweight	$50
Nov-15-21	Initiated	Jefferies	Buy	$30

Show Previous Ratings

Oct-26-25 06:43AM	Ventyx Biosciences Reports Positive Phase 2 Data for Oral NLRP3 Inhibitor VTX3232 in Obesity and Cardiovascular Risk (Insider Monkey)
Oct-23-25 07:36AM	Ventyx shares soar after study suggests cardiovascular benefits for experimental drug (BioPharma Dive) +70.98%
Oct-22-25 04:02PM	Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors (GlobeNewswire)
Oct-09-25 12:00PM	Ventyx Biosciences, Inc. (VTYX) Is Up 20.81% in One Week: What You Should Know (Zacks)
Aug-27-25 07:02AM	Ventyx Biosciences to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
04:05PM	Loading…
Aug-07-25 04:05PM	Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress (GlobeNewswire) -6.72% +19.07%
Jul-10-25 12:00PM	Ventyx Biosciences (VTYX) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks) +18.33%
Jun-18-25 05:54AM	Ventyx reports positive outcomes from trial of VTX3232 for Parkinsons (Clinical Trials Arena) +7.73%
Jun-17-25 07:00AM	Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson's Disease (GlobeNewswire) -13.39%
May-28-25 08:00AM	Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-08-25 04:01PM	Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress (GlobeNewswire) +5.98%
Apr-01-25 07:00AM	Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists (GlobeNewswire) -6.96%
Feb-27-25 04:05PM	Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress (GlobeNewswire) -5.23% +8.97%
Feb-18-25 08:00AM	Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn's Disease at ECCO 2025 (GlobeNewswire)
Feb-05-25 08:00AM	Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
08:11AM	Loading…
Jan-15-25 08:11AM	Ventyx Biosciences highlights its 2025 pipeline strategy (TipRanks)
Jan-14-25 08:00AM	Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio (GlobeNewswire)
Nov-12-24 11:01PM	Ventyx Biosciences Reports Q3 Financial Results and Pipeline Progress (TipRanks)
07:30AM	Ventyx Biosciences to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Nov-07-24 04:05PM	Ventyx Biosciences Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Progress (GlobeNewswire)
Oct-29-24 06:01AM	These 2 Strong Buy Penny Stocks Could Rally Over 500%, Say Analysts (TipRanks)
Oct-15-24 08:00AM	Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024 (GlobeNewswire)
Sep-23-24 01:54PM	Sanofi gains exclusivity rights to Ventyxs CNS-penetrant drug in $27m deal (Pharmaceutical Technology) +6.96%
08:00AM	Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi (GlobeNewswire)
Sep-06-24 08:00AM	Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson's Disease (GlobeNewswire)
Aug-30-24 08:00AM	Ventyx Biosciences Announces Departure of Chief Financial Officer (GlobeNewswire)
07:04AM	Novo builds heart failure case for semaglutide; Ventyx CFO departs (BioPharma Dive)
Aug-28-24 08:00AM	Ventyx Biosciences to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Aug-08-24 04:01PM	Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress (GlobeNewswire)
Jul-30-24 05:13PM	Ventyx scraps TYK2 inhibitor after Phase II Crohns defeat (Pharmaceutical Technology)
08:00AM	Loading…
Jul-29-24 08:00AM	Ventyxs TYK2 drug suffers second setback (BioPharma Dive) -22.71%
08:00AM	Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Participants with Moderately to Severely Active Crohn's Disease (GlobeNewswire)
Jun-05-24 04:01PM	Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers (GlobeNewswire) +6.77% -37.78%
May-16-24 04:05PM	Ventyx Biosciences to Participate in Three Upcoming Investor Conferences (GlobeNewswire) +18.85% -5.02%
11:23AM	Ventyx Biosciences Appoints Matthew Moore as Chief Operating Officer; Shares Rise (MT Newswires)
08:00AM	Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer (GlobeNewswire)
May-13-24 09:02PM	VTYX ALERT: Top Law Firm Bleichmar Fonti & Auld LLP Is Investigating the Directors of Ventyx Biosciences, Inc. for Potential Breaches of Fiduciary Duty; Contact the Firm for More Details (Newsfile)
10:37AM	Ventyx Biosciences, Inc. (NASDAQ:VTYX) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 08:59PM	VTYX Stock Earnings: Ventyx Biosciences Beats EPS for Q1 2024 (InvestorPlace) -8.71%
04:01PM	Ventyx Biosciences Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Progress (GlobeNewswire)
May-02-24 04:05PM	Ventyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024 (GlobeNewswire)
Apr-30-24 12:00PM	What Makes Ventyx Biosciences (VTYX) a New Buy Stock (Zacks)
Apr-17-24 08:45AM	NASDAQ: VTYX Lawsuit Notice: Investors who lost over $100,000 with shares of Ventyx Biosciences, Inc. (NASDAQ: VTYX) should contact the Shareholders Foundation (GlobeNewswire) -7.98%
05:45AM	Ventyx Biosciences, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your Rights - VTYX (PR Newswire)
Apr-15-24 01:15PM	Investors who lost over $100,000 with Ventyx Biosciences, Inc. (NASDAQ: VTYX) between October 2021 to November 2023, should contact the Shareholders Foundation in connection with Lawsuit (PR Newswire)
Mar-27-24 06:20AM	Investors in Ventyx Biosciences, Inc. Should Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your Rights - VTYX (PR Newswire)
Mar-20-24 05:45AM	Ventyx Biosciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your Rights - VTYX (PR Newswire) -5.06%
Mar-18-24 06:02PM	Robbins LLP Urges VTYX Investors with Large Losses to Contact the Firm Before April 30, 2024, for Information About Their Rights (Business Wire)
Mar-11-24 07:29AM	Ventyx Biosciences, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; April 30, 2024 deadline (GlobeNewswire) -18.95%
07:00AM	Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event (GlobeNewswire)
Mar-07-24 08:52AM	NodThera says inflammation drug has positive effect in Parkinsons (BioPharma Dive) +13.18%
08:00AM	Ventyx Biosciences Announces $100 Million Private Placement of Common Stock (GlobeNewswire)
Mar-06-24 08:00AM	Ventyx Biosciences to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Mar-04-24 08:00AM	Ventyx Biosciences to Host Virtual Investor Event on March 11, 2024 (GlobeNewswire) +5.88%
Feb-27-24 04:01PM	Ventyx Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Corporate Progress (GlobeNewswire) +28.43%
Feb-22-24 07:00AM	Ventyx Biosciences to Present Results of the Phase 2 Trial of VTX002 in Ulcerative Colitis at the 19th Congress of the European Crohn's and Colitis Organisation (ECCO) (GlobeNewswire) +14.48%
Feb-21-24 04:09PM	Weight-Loss Drug Hype Sends Biotech Ventyxs Stock Soaring on Rivals Data (Bloomberg) +68.56%
Feb-06-24 04:05PM	Ventyx Biosciences to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire) -5.13%
Dec-23-23 11:01AM	Ventyx Biosciences Inc CEO Raju Mohan Sells 58,860 Shares (GuruFocus.com)
Nov-21-23 04:05PM	Ventyx Biosciences to Participate in the 35th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-10-23 08:00AM	Ventyx Biosciences to Participate in the Jefferies London Healthcare Conference (GlobeNewswire) -7.17%
Nov-09-23 04:01PM	Ventyx Biosciences Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Progress (GlobeNewswire) -5.15%
09:35AM	Down -86.57% in 4 Weeks, Here's Why Ventyx Biosciences, Inc. (VTYX) Looks Ripe for a Turnaround (Zacks)
Nov-07-23 04:20PM	Ventyx Crashes 81% After Scrapping Two Studies On A Psoriasis Treatment Flop (Investor's Business Daily) -80.62%
08:47AM	Why Is Ventyx Biosciences (VTYX) Stock Down 76% Today? (InvestorPlace)
07:00AM	Ventyx revises TYK2 drug plans after lackluster study data (BioPharma Dive)
Nov-06-23 04:01PM	Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Patients with Moderate to Severe Plaque Psoriasis and Provides Corporate Update (GlobeNewswire) -9.56%
Nov-04-23 12:16PM	12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds (Insider Monkey)
Oct-11-23 11:37AM	Ventyx (VTYX) Down Despite Positive Ulcerative Colitis Study Data (Zacks) -8.87%
Oct-10-23 04:18PM	These Stocks Are Moving the Most Today: PepsiCo, Truist, Unity Software, Rivian, Electronic Arts, and More (Barrons.com) -25.93%
12:55PM	Why Shares of Ventyx Biosciences Are Dropping Tuesday (Motley Fool)
07:44AM	Health Care Roundup: Market Talk (The Wall Street Journal)
Oct-09-23 04:01PM	Ventyx Biosciences Announces Positive Results from the Phase 2 Trial of VTX002 in Patients with Moderate-to-Severely Active Ulcerative Colitis (GlobeNewswire)
Oct-07-23 05:00AM	CEO Raju Mohan Sells 30,000 Shares of Ventyx Biosciences Inc (VTYX) (GuruFocus.com)
Oct-04-23 11:01PM	Insider Sell: Christopher Krueger Sells 15,000 Shares of Ventyx Biosciences Inc (VTYX) (GuruFocus.com) -5.98%
Sep-29-23 12:43PM	25 Biggest Stocks with Negative Beta (Insider Monkey)
Sep-08-23 05:07PM	Insider Sell: CFO Martin Auster Sells 26,472 Shares of Ventyx Biosciences Inc (GuruFocus.com)
Aug-30-23 04:05PM	Ventyx Biosciences to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Aug-15-23 07:23AM	Ventyx Biosciences, Inc. (NASDAQ:VTYX) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-10-23 04:01PM	Ventyx Biosciences Reports Second Quarter 2023 Financial Results and Highlights Recent Corporate Progress (GlobeNewswire) +6.38%
Aug-03-23 04:05PM	Ventyx Biosciences to Report Second Quarter 2023 Financial Results on August 10, 2023 (GlobeNewswire)
Aug-02-23 04:06PM	Ventyx Biosciences to Participate in the Canaccord Genuity 43rd Annual Growth Conference (GlobeNewswire)
Jul-12-23 07:22AM	Daily Vickers Top Buyers & Sellers for 07/12/2023 (Argus Research) -5.95%
Jul-03-23 02:09PM	Why Shares of Ventyx Biosciences Rose Monday (Motley Fool) +22.87%
Jun-14-23 07:00AM	Ventyx Biosciences Announces Initiation of Dosing in a Phase 1 Trial of VTX3232, a Novel CNS-Penetrant NLRP3 Inhibitor (GlobeNewswire)
Jun-07-23 07:00AM	Ventyx Biosciences Announces Completion of Enrollment of the Phase 2 Trial of VTX002 in Ulcerative Colitis and the Phase 2 Trial of VTX958 in Plaque Psoriasis (GlobeNewswire)
May-31-23 08:00AM	Ventyx Biosciences to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
May-12-23 08:57AM	Q1 2023 Ventyx Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) -7.11%
May-11-23 04:01PM	Ventyx Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress (GlobeNewswire)
May-04-23 04:05PM	Ventyx Biosciences to Report First Quarter 2023 Financial Results on May 11, 2023 (GlobeNewswire)
Mar-27-23 07:12AM	Ventyx Biosciences, Inc. (NASDAQ:VTYX) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-24-23 11:13AM	Q4 2022 Ventyx Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) -5.23%
08:00AM	Ventyx Biosciences to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference (GlobeNewswire)
Mar-23-23 04:01PM	Ventyx Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Corporate Progress (GlobeNewswire)
Mar-15-23 04:05PM	Ventyx Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 23, 2023 (GlobeNewswire)
Mar-13-23 09:02AM	Companies Like Ventyx Biosciences (NASDAQ:VTYX) Are In A Position To Invest In Growth (Simply Wall St.)
Mar-11-23 01:21PM	Ventyx Biosciences Provides Update on Silicon Valley Bank Financial Exposure (GlobeNewswire)
Feb-28-23 08:00AM	Ventyx Biosciences to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Feb-27-23 08:50AM	Recent Price Trend in Ventyx Biosciences, Inc. (VTYX) is Your Friend, Here's Why (Zacks)
Feb-13-23 09:55AM	Wall Street Analysts See a 26.67% Upside in Ventyx Biosciences, Inc. (VTYX): Can the Stock Really Move This High? (Zacks)

Ventyx Biosciences, Inc. engages in developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded by Raju S. Mohan on November 21, 2018 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Nuss John	CHIEF SCIENTIFIC OFFICER	Apr 02 '25	Sale	1.07	1,887	2,019	467,226	Apr 03 04:21 PM
Mohan Raju	CEO AND PRESIDENT	Mar 28 '25	Option Exercise	0.00	11,844	0	2,303,540	Apr 01 04:36 PM
Nuss John	CHIEF SCIENTIFIC OFFICER	Mar 28 '25	Option Exercise	0.00	4,531	0	469,113	Apr 01 04:35 PM
Nuss John	CHIEF SCIENTIFIC OFFICER	Dec 27 '24	Sale	2.36	21,119	49,841	464,582	Dec 30 05:33 PM
Nuss John	Officer	Dec 27 '24	Proposed Sale	2.36	21,119	49,842		Dec 27 04:46 PM
Gujrathi Sheila	Director	Dec 23 '24	Buy	2.31	130,000	300,573	130,000	Dec 26 08:05 PM
Nuss John	CHIEF SCIENTIFIC OFFICER	Dec 17 '24	Option Exercise	0.00	34,930	0	498,862	Dec 19 06:50 PM
Nuss John	CHIEF SCIENTIFIC OFFICER	Dec 19 '24	Sale	2.26	13,161	29,682	485,701	Dec 19 06:50 PM
Mohan Raju	CEO AND PRESIDENT	Dec 17 '24	Option Exercise	0.00	116,668	0	2,291,696	Dec 19 06:49 PM
Nuss John	Officer	Dec 19 '24	Proposed Sale	2.26	13,161	29,682		Dec 19 06:48 PM
Nuss John	CHIEF SCIENTIFIC OFFICER	Dec 10 '24	Option Exercise	0.20	198,934	39,787	463,932	Dec 11 05:21 PM
Mohan Raju	CEO AND PRESIDENT	Nov 25 '24	Buy	2.01	261,752	524,944	2,175,028	Nov 25 09:07 PM
Mohan Raju	CEO AND PRESIDENT	Nov 22 '24	Buy	1.83	238,248	434,946	1,913,276	Nov 25 09:07 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VTYX

Ventyx Biosciences Inc

Upgrade your FINVIZ experience